Zobrazeno 1 - 10
of 148
pro vyhledávání: '"F, van den Hoogen"'
Autor:
B. Hezer, M. E. J. Reinders, M. W. F. van den Hoogen, M. Tielen, J. van de Wetering, D. A. Hesselink, E. K. Massey
Publikováno v:
Transplant International, Vol 37 (2024)
After transplantation self-management is essential for graft survival and optimal quality of life. To address the need for home-based support in self-management, we implemented the “SelfCare after Renal Transplantation” (SeCReT) box, containing h
Externí odkaz:
https://doaj.org/article/4565e24a0c5b4dc29de059552a8c92c5
Autor:
H. Tejeda-Mora, J. G. H. P. Verhoeven, W. Verschoor, K. Boer, D. A. Hesselink, M. W. F. van den Hoogen, L. J. W. van der Laan, C. C. Baan, R. C. Minnee, M. J. Hoogduijn
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract The diagnosis of kidney allograft rejection is based on late histological and clinical markers. Early, specific and minimally-invasive biomarkers may improve rejection diagnosis. Endothelial cells (EC) are one of the earliest targets in kidn
Externí odkaz:
https://doaj.org/article/04791b937768459698233c55be9dff03
Autor:
A. van Caam, J. Aarts, T. van Ee, E. Vitters, M. Koenders, F. van de Loo, P. van Lent, F. van den Hoogen, R. Thurlings, M. C. Vonk, P. M. van der Kraan
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Introduction The pathophysiology of systemic sclerosis (SSc) is closely linked to overactive TGFβ signaling. TGFβ is produced and circulates in latent form, making its activation crucial for signaling. This activation can be mediated via i
Externí odkaz:
https://doaj.org/article/62febe8d581a411eb1e85ab1a13c79e8
Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
Autor:
Marieke van der Zwan, Marian C. Clahsen-Van Groningen, Martijn W. F. van den Hoogen, Marcia M. L. Kho, Joke I. Roodnat, Katya A. L. Mauff, Dave L. Roelen, Madelon van Agteren, Carla C. Baan, Dennis A. Hesselink
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Rabbit anti-thymocyte globulin (rATG) is currently the treatment of choice for glucocorticoid-resistant, recurrent, or severe acute allograft rejection (AR). However, rATG is associated with severe infusion-related side effects. Alemtuzumab is incide
Externí odkaz:
https://doaj.org/article/84cfde96c8d84de9a1b29aa2dd8191e6
Autor:
C. M. den Hoed, Stefan Roest, H De Geus, R. J. van Thiel, Jos A. Bekkers, Olivier C. Manintveld, Robert C. Minnee, Leonard Seghers, M. W. F. van den Hoogen, Dennis A. Hesselink
Publikováno v:
Journal of Critical Care, 64, 37-44. Elsevier
All transplant recipients receive tacrolimus, mycophenolate and glucocorticoids and these drugs have many side-effects and drug-drug interactions. Common complications include surgical complications, infections, rejection and acute kidney injury. Inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9af41852a061ef8f686fdc2e927734f5
https://doi.org/10.1016/j.jcrc.2021.03.003
https://doi.org/10.1016/j.jcrc.2021.03.003
Publikováno v:
The Lancet Healthy Longevity, 3(11). Elsevier Ltd.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a68d154c084d55c3f7ed2f5f7796b16
https://pubmed.ncbi.nlm.nih.gov/36480980
https://pubmed.ncbi.nlm.nih.gov/36480980
Autor:
C. Michielsens, N. den Broeder, F. van den Hoogen, E. Mahler, S. Teerenstra, D. van der Heijde, L. M. Verhoef, A. den Broeder
Publikováno v:
Annals of the Rheumatic Diseases. 81:172-173
BackgroundTumour Necrosis Factor inhibitors (TNFi) are effective in Psoriatic Arthritis (PsA) and axial SpondyloArthritis (axSpA), but are associated with a somewhat increased infection risk, patient burden, and high costs. Treat-to-target (T2T) tape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5174b5e1144434999b3d077a0db5ad4
https://doi.org/10.1136/annrheumdis-2022-eular.1430
https://doi.org/10.1136/annrheumdis-2022-eular.1430
Autor:
N. Den Broeder, L. M. Verhoef, Y. A. De Man, M. R. Kok, R. M. Thurlings, W. Van der Weele, B. Van den Bemt, F. Van den Hoogen, A. Van der Maas, A. Den Broeder
Publikováno v:
Annals of the Rheumatic Diseases. 81:597.2-598
BackgroundThe optimal rituximab (RTX) dose for the treatment of rheumatoid arthritis remains unclear. RTX treatment of 1000mg per 6 months and 2000mg per 6 months were shown to be similarly efficacious (1). The REDO trial showed comparable the 6-mont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::401b9dddab9c5e268da221004f73fc6e
https://doi.org/10.1136/annrheumdis-2022-eular.2903
https://doi.org/10.1136/annrheumdis-2022-eular.2903
Autor:
M. L. M. Mulder, J. E. Vriezekolk, T. Van Hal, L. Nieboer, N. Den Broeder, E. M. G. J. De Jong, A. Den Broeder, F. Van den Hoogen, P. Helliwell, M. Wenink
Publikováno v:
Annals of the Rheumatic Diseases. 81:259.1-259
BackgroundConventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) are the cornerstone first-line treatment in psoriatic arthritis (PsA), although there is a paucity of evidence for the effectiveness of csDMARDs and especially their c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0940fe0c732ad4712c4b4427eca6b31a
https://doi.org/10.1136/annrheumdis-2022-eular.2042
https://doi.org/10.1136/annrheumdis-2022-eular.2042
Autor:
N. Den Broeder, A. Den Broeder, L. M. Verhoef, F. Van den Hoogen, A. Van der Maas, B. Van den Bemt
Publikováno v:
Annals of the Rheumatic Diseases. 81:593.2-594
BackgroundTocilizumab (TCZ) and sarilumab (SRL) are IL6-receptor antagonists registered for the treatment of rheumatoid arthritis (RA). Data from extension of the ASCERTAIN trial showed that patients responding to blinded intravenous (IV) TCZ rarely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03be81341cde95b30e41404267b18fe0
https://doi.org/10.1136/annrheumdis-2022-eular.2156
https://doi.org/10.1136/annrheumdis-2022-eular.2156